# A case of anastomotic recurrence 12 years after intersphincteric resection for anorectal malignant melanoma

**Authors:** Sato Nishida, Tatsuya Shonaka, Tomohiro Takeda, Masahide Otani, Mizuho Ohara, Chikayoshi Tani, Manami Hayashi, Tomoe Nakagawa, Kimiharu Hasegawa, Hideki Yokoo

PMC · DOI: 10.1007/s12328-025-02140-z · Clinical Journal of Gastroenterology · 2025-05-04

## TL;DR

A rare case of anorectal malignant melanoma recurrence 12 years after surgery is reported, highlighting the need for long-term follow-up.

## Contribution

This paper presents a rare case of long-term recurrence after AMM surgery, emphasizing the importance of extended follow-up.

## Key findings

- An 80-year-old woman experienced anastomotic recurrence 12 years after intersphincteric resection for AMM.
- Both initial and recurrent tumor specimens were negative for BRAF V600E/K mutations.
- The patient remained recurrence-free four months after reoperation with nivolumab treatment.

## Abstract

Anorectal malignant melanoma (AMM) is a rare disease with a poor prognosis, accounting for < 1.0% of all malignant melanomas and a 5-year survival rate of 19.2%. The treatment is mainly surgical, and lymph-node dissection is often performed. Cases of recurrence after a prolonged period (> 10 years), as in the present case, are rare. The patient was an 80-year-old woman who underwent laparoscopic intersphincteric resection with bilateral lateral lymph-node dissection for the diagnosis of primary AMM of the lower rectum at X – 12 years. The pathology was pStage III and the resection margins were negative. Twelve years after the initial surgery, in year X, the patient visited our hospital with the chief complaint of discomfort due to a tumor in the anorectal region. Biopsy revealed a recurrence, and laparoscopic abdominoperineal resection was performed. Based on the pathological findings, the patient was diagnosed with local recurrence of the anastomotic anal canal. Both the first and second specimens were negative for BRAF V600E/K mutation. Four months have passed since the surgery, and the patient continued to receive nivolumab without recurrence. Long-term local follow-up is necessary when the anal canal is preserved during AMM surgery.

## Linked entities

- **Genes:** BRAF (B-Raf proto-oncogene, serine/threonine kinase) [NCBI Gene 673]
- **Diseases:** melanoma (MONDO:0005105)

## Full-text entities

- **Genes:** BRAF (B-Raf proto-oncogene, serine/threonine kinase) [NCBI Gene 673] {aka B-RAF1, B-raf, BRAF-1, BRAF1, NS7, RAFB1}
- **Diseases:** tumor (MESH:D009369), AMM (MESH:D008545), pStage III (MESH:C537189)
- **Chemicals:** nivolumab (MESH:D000077594)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** V600E/K

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12310788/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12310788/full.md

## References

1 references — full list in the complete paper: https://tomesphere.com/paper/PMC12310788/full.md

---
Source: https://tomesphere.com/paper/PMC12310788